Strs Ohio lifted its stake in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 658.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,200 shares of the company’s stock after purchasing an additional 15,800 shares during the quarter. Strs Ohio’s holdings in Deciphera Pharmaceuticals were worth $704,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of DCPH. Northern Trust Corp increased its holdings in shares of Deciphera Pharmaceuticals by 12.8% in the first quarter. Northern Trust Corp now owns 84,732 shares of the company’s stock valued at $1,698,000 after purchasing an additional 9,640 shares during the last quarter. BlackRock Inc. grew its position in Deciphera Pharmaceuticals by 37.5% in the first quarter. BlackRock Inc. now owns 499,879 shares of the company’s stock worth $10,018,000 after acquiring an additional 136,396 shares during the period. Russell Investments Group Ltd. purchased a new position in Deciphera Pharmaceuticals in the first quarter worth approximately $884,000. Emerald Advisers Inc. PA grew its position in Deciphera Pharmaceuticals by 23.0% in the second quarter. Emerald Advisers Inc. PA now owns 592,224 shares of the company’s stock worth $23,304,000 after acquiring an additional 110,785 shares during the period. Finally, Emerald Mutual Fund Advisers Trust grew its position in Deciphera Pharmaceuticals by 18.3% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 512,180 shares of the company’s stock worth $20,154,000 after acquiring an additional 79,120 shares during the period. 53.52% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on DCPH. BidaskClub lowered Deciphera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 19th. Zacks Investment Research lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Wednesday, October 3rd. ValuEngine upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. Finally, Leerink Swann began coverage on Deciphera Pharmaceuticals in a research report on Monday, September 24th. They issued an “underperform” rating and a $28.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has an average rating of “Buy” and an average target price of $45.44.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.03. Equities research analysts predict that Deciphera Pharmaceuticals Inc will post -2.61 EPS for the current year.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.